IRWD — Ironwood Pharmaceuticals Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedMid CapNeutral

Annual cashflow statement for Ironwood Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	21.5	106	528	175	-1,032
Depreciation
Amortisation
Deferred Taxes
Non-Cash Items	83.6	60	47.5	28.7	1,129
Discontinued Operations
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-100	-0.941	17.7	2.82	11.3
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accrued Expenses
Change in Payable / Accrued Expenses
Change in Other Liabilities
Cash from Operating Activities	10.7	169	262	274	183
Capital Expenditures	-7.19	-1.84	-0.265	-0.136	-1,026
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-3.96	—	0	—	—
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-11.1	-1.84	-0.265	-0.136	-1,026
Financing Cash Flow Items	-9.05	—	0	—	-29.2
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-1.19	18.5	-4.55	-238	277
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-1.6	186	257	36.1	-566